Rigel Pharmaceuticals, Inc.
RIGL
$46.00
$1.593.58%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -31.69% | 90.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -31.69% | 90.66% | |||
| Cost of Revenue | 6.90% | -11.83% | |||
| Gross Profit | -36.53% | 123.18% | |||
| SG&A Expenses | -1.10% | 5.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.13% | 0.05% | |||
| Operating Income | -53.49% | 378.38% | |||
| Income Before Tax | -53.95% | 421.08% | |||
| Income Tax Expenses | -175.88% | 467.69% | |||
| Earnings from Continuing Operations | -53.20% | 420.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -53.20% | 420.82% | |||
| EBIT | -53.49% | 378.38% | |||
| EBITDA | -52.97% | 361.31% | |||
| EPS Basic | -53.60% | 418.61% | |||
| Normalized Basic EPS | -54.34% | 418.84% | |||
| EPS Diluted | -55.49% | 420.63% | |||
| Normalized Diluted EPS | -56.34% | 421.24% | |||
| Average Basic Shares Outstanding | 0.86% | 0.43% | |||
| Average Diluted Shares Outstanding | 5.47% | -0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||